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1. INTRODUCTION 1,2,3,4 
             Analytical chemistry may be defined as the “Science and art of determining the 
composition of materials in terms of the elements or compounds contained”.  
Analytical method is a specific application of a technique to solve an analytical 
problem.  The use of instrumentation is an exciting and fascinating part of chemical 
analysis that interacts with all areas of chemistry and with many other areas of pure and 
applied science. Analytical instrumentation plays an important role in the production and 
evaluation of new products and in the protection of consumers and the environment. This 
instrumentation provides the lower detection limits required to assure safe foods, drugs, 
water and air. The manufacture of materials, whose composition must be known 
precisely, is to be monitored by analytical instruments. 
Types of Instrumentation5 
A) Spectrometric Techniques 
o Atomic Spectrometry (Emission and Absorption) 
o Electron Spin Resonance Spectroscopy 
o Fluorescence and phosphorescence Spectrophotometry 
o Infrared Spectrophotometry 
o Nuclear Magnetic Resonance Spectroscopy 
o Radiochemical Techniques including activation analysis 
o Raman Spectroscopy 
o Ultraviolet and visible Spectrophotometry 
o X-Ray Spectroscopy    
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B) Chromatographic Techniques 
o Gas Chromatography 
o High performance Liquid Chromatography 
o Thin Layer Chromatography 
C) Miscellaneous Techniques 
o Kinetic Techniques  
o Mass Spectrometry 
o Thermal Analysis 
D) Hyphenated Techniques 
o GC-MS (Gas Chromatography – Mass Spectrometry) 
o ICP-MS (Inductivity Coupled Plasma- Mass Spectrometry) 
o GC-IR (Gas Chromatography – Infrared Spectroscopy) 
o MS-MS (Mass Spectrometry – Mass Spectrometry)                                   
                                               HPLC  
HPLC is a modern technique, it is a much more reliable and reproducible method 
for the standardization of both single and compound formulation. HPLC is a separation 
technique based on a stationary phase and a liquid mobile phase. Separations are 
achieved by partition, adsorption or ion exchange process, depending upon the size of 
stationary phase used. 
HPLC is one of the most versatile instruments used in the field of pharmaceutical 
analysis. It provides the following features. 
 High resolving power 
 Speedy separation 
 Continuous monitoring of the column effluent 
 Accurate quantitative measurement 
 Repetitive and reproducible analysis using the same column 
 Automation of the analytical procedure and data handling. 
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Modes in HPLC 
Quantitative methods 
In all HPLC analysis, we are interested either in qualitative or quantitative 
determination of the different components present in the sample. 
Qualitative analysis (Identification) 
Initial identification of different components of the sample should be made by 
comparing retention time (RT) of different analytes with that of standard. Since, many 
substances can have similar RT values, use of different chromatographic parameters 
(different MP, different column, flow rate) to confirm the identity of the compound. 
TYPES OF HPLC TECHNIQUES 
Based on modes of chromatography: 
 Normal phase chromatography 
 Reverse phase chromatography 
Based on principle of separation: 
 Adsorption chromatography 
 Ion exchange chromatography 
 Size exclusion chromatography 
 Affinity chromatography 
 Chiral phase chromatography 
Base on elution technique: 
 Isocratic separation  
 Gradient separation 
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Based on the scale of operation: 
 Analytical HPLC  
 Preparative HPLC 
NORMAL PHASE CHROMATOGRAPHY. 
 Mechanism: Retention by interaction of the polar surface of stationary phase with 
polar parts of the sample molecules.  
 
 Stationary Phase:  It is a bonded siloxane with polar functional groups like SiO2, 
Al2O3, -NH2, -CN, -NO2, - Diol.  
 
 Mobile Phase: Nonpolar solvents like heptane, hexane, cyclohexane, chloroform, 
ethyl ether, and dioxane.  
 Application: Separation of nonionic, nonpolar to medium and polar substances. 
 Sample Elution Order: Least polar components are eluted first. 
REVERSE PHASE CHROMATOGRAPHY   
 Mechanism: Retention by interaction of the nonpolar hydrocarbon chain of 
stationary phase with nonpolar parts of sample molecules. 
 
 Stationary Phase:  It is bonded siloxane with nonpolar functional groups like n-
octadecyl (C18) or n-octyl (C8), ethyl, phenyl, -(CH2) n-diol, -(CH2)n-CN. 
 
 Mobile Phase: Polar solvents like methanol, acetonitrile, water or buffer  
(Sometimes with additives of THF or dioxane). 
 Application: Separation of nonionic and ion forming nonpolar to medium polar 
substances. 
 
 Sample Elution Order: Most polar components are eluted first. 
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PRINCIPLES OF SEPARATION 
Adsorption chromatography employs high-surface area particles that absorb the solute 
molecules. Usually a polar solid such as a silica gel, alumina or porous glass beads and a 
non-polar mobile phase such as heptane, octane or chloroform are used in adsorption 
chromatography. In adsorption chromatography, adsorption process is described by 
competition model and solvent interaction model.  
ION-EXCHANGE CHROMATOGRAPHY 
Separation is based on the charge-bearing functional groups, anion exchange for sample 
negative ion, or cation exchange - for sample positive ion. Gradient elution by pH is 
common. 
 SIZE EXCLUSION CHROMATOGRAPHY 
Also known as gel permeation or filtration, separation is based on the molecular size or 
hydrodynamic volume of the components. Molecules that are too large for the pores of 
the porous packing material on the column elute first, small molecules that enter the 
pores elute last, and the elution rates of the rest depend on their relative sizes. 
AFFINITY/ ION-PAIR CHROMATOGRAPHY 
 Separation is based on a chemical interaction specific to the target species. The 
more popular reversed phase mode uses a buffer and an added counter-ion of opposite 
charge to the sample with separation being influenced by pH, ionic strength, temperature, 
concentration of and type of organic co-solvent(s). Affinity chromatography, common for 
macromolecules, employs a ligand (biologically active molecule bonded covalently to the 
solid matrix) which interacts with its homologous antigen (analyte) as a reversible 
complex that can be eluted by changing buffer conditions. 
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CHIRAL CHROMATOGRAPHY: 
 Separation of the enantiomers can be achieved on chiral stationary phases by 
formation of diastereomers via derivatizing agents or mobile phase additives on a chiral 
stationary phase. When used as an impurity test method, the sensitivity is enhanced if the 
enantiomeric impurity elutes before the enantiomeric drug. 
 ISOCRATIC SEPARATION: 
 In this technique, the same mobile phase combination is used throughout the 
process of separation. The same polarity or elution strength is maintained the process. 
GRADIENT SEPARATION: 
 In this technique, a mobile phase combination of lower polarity or elution strength 
is used followed by gradually increasing the polarity or elution strength. 
ANALYTICAL HPLC: 
 In this only analysis of the samples are done. Recovery of the samples for reusing 
is normally not done, since the samples used are very low. 
PREPARATIVE HPLC: 
 Where analysis of the individual fractions of pure compounds can be collected 
using fraction collector. The collected samples are reused. 
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INSTRUMENTATION7               
 
                                 Typical diagram of HPLC8 
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The individual components HPLC and their working functions are described.8 
SOLVENT DELIVERY SYSTEM 
The most important component of HPLC in solvent delivery system is the pump, 
because its performance directly effects the retention time, reproducibility and detector 
sensitivity. Among the several solvent delivery systems,  
            Direct gas pressure, Pneumatic intensifier, Reciprocating pump with twin or triple 
pistons is widely used, as this system gives less baseline noise, good flow rate 
reproducibility etc.  
MOBILE PHASE 
         The following points should also be considered when choosing a mobile phase: 
1. It is essential to establish that the drug is stable in the mobile phase for at least the 
duration of the analysis. 
2. Excessive salt concentrations should be avoided. High salt concentrations can 
result in precipitation, which can damage HPLC equipment. 
3. The mobile phase should have a pH 2.5 and pH 7.0 to maximize the lifetime of the 
column. 
4. Reduce cost and toxicity of the mobile phase by using methanol instead of 
acetonitrile when possible. 
5. Minimize the absorbance of buffer. Since trifluoroacetic acid, acetic acid or formic 
acid absorb at shorter wavelengths, they may prevent detection of products 
without chromophores above 220 nm. Carboxylic acid modifiers can be frequently 
replaced by phosphoric acid, which does not absorb above 200 nm. 
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6. Use volatile mobile phases when possible, to facilitate collection of products and 
LC-MS analysis. Volatile mobile phases include ammonium acetate, ammonium 
phosphate, formic acid, acetic acid, and trifluoroacetic acid. Some caution is 
needed as these buffers absorb below 220 nm. 
SOLVENT DEGASSING SYSTEM 
The constituents of the mobile phase should be degassed and filtered before use. 
Several methods are employed to remove the dissolved gases in the mobile phase. They 
include 
 Heating and stirring, Vacuum degassing with an aspirator, Filtration through 0.45 
filter, Vacuum degassing with an air-soluble membrane, Helium purging , purging or 
combination of these methods. HPLC systems are also provided an online degassing 
system, which continuously removes the dissolved gases from the mobile phase. 
GRADIENT ELUTION DEVICES 
HPLC columns may be run isocratically, i.e., with constant eluent or they may be 
run in the gradient elution mode in which the mobile phase composition varies during 
run. Gradient elution over comes the problem of dealing with a complex mixture of 
solutes.  
 COLUMNS 
The heart of the system is the column. The choice of common packing material 
and mobile phases depends on the physical properties of the drug. The flow chart in 
Table.1 can assist one in determining which columns to examine. Many different reverse 
phase columns will provide excellent specificity for any particular separation. It is 
therefore best to routinely attempt separations with a standard C8 or C18 column and 
determine if it provides good separations. If this column does not provide good separation 
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or the mobile phase is unsatisfactory, alternate methods or columns should be explored. 
Reverse phase columns differ by the carbon chain  
                                                      
                                                
COLUMN PACKING: 
The packing used in modern HPLC consist of small, rigid particles having a 
narrow particle size distribution. There are three main type of column packing in 
HPLC. 
 Porous, Polymeric Beads 
Porous, polymeric beds based on styrene divinyl benzene co-polymers used for 
ion exchange and size exclusion chromatography. For analytical purpose these 
have now been replaced by silica based packing which are more efficient and 
more stable. 
 Porous Layer Beds  
This consisting of a thin shell (1-3 µm) of silica or modified silica on a 
spherical inert core (e.g. glass). After the development of totally porous micro 
particulate packing, these have not been used in HPLC. 
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 Totally Porous Silica Particles (dia. <10 µm) 
Particles of diameter >20µm are usually dry packed. While particles of diameter 
<20µm are slurry packed in which particles are suspended on a suitable solvent 
and the slurry is driven into the column under pressure. 
SAMPLE INTRODUCTION SYSTEM 
Two means for analyte introduction on the column are injection into a 
    Flowing stream,  Stopflowinjection, Rheodyne injector. These techniques can 
be used with a syringe or an injection valve. Automatic injector is a microprocessor-
controlled version of the manual universal injector. Usually, up to 100 samples can be 
loaded in to the auto injector tray. The system parameters such as flow rates, gradient, run 
time, volume to be injected, etc. are chosen, stored in memory and sequentially executed 
on consecutive injections.  
                                     
INJECTORS 
Sample introduction can be accomplished in various ways. The simplest method is to use 
an injection valve. In more sophisticated LC systems, automatic sampling devices are 
incorporated where sample introduction is done with the help of autosamplers and 
microprocessors. 
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In liquid chromatography, liquid samples may be injected directly and solid samples need 
only be dissolved in an appropriate solvent. The solvent need not be the mobile phase, 
but frequently it is judiciously chosen to avoid detector interference, column/component 
interference, and loss in efficiency. 
TEMPERATURE 
Room temperature is the first choice. Elevated temperatures are some times used 
to reduce column pressure or enhance selectivity. Typically, temperatures in excess of 
600C are not used. 
  LIQUID CHROMATOGRAPHIC DETECTORS 
 UV/Visible Detector  
A versatile, dual-wavelength absorbance detector for HPLC. This detector offers the high 
sensitivity required for routine UV-based applications to low-level impurity identification 
and quantitative analysis.  
 
 Photodiode Array (PDA) Detector  
Offers advanced optical detection for Waters analytical HPLC, preparative HPLC, or 
LC/MS system solutions. Its integrated software and optics innovations deliver high 
chromatographic and spectral sensitivity.  
 
 Refractive Index (RI) Detector  
Offers high sensitivity, stability and reproducibility, making this detector the ideal 
solution for analysis of components with limited or no UV absorption.  
 
 Multi-Wavelength Fluorescence Detector  
Offers high sensitivity and selectivity fluorescence detection for quantitating low 
concentrations of target compounds.  
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Evaporative Light Scattering (ELS) Detector  
A compact detector that controls temperatures in both the nebulization and evaporation 
stages, maintaining low-dispersion characteristics for dependable HPLC/ELS results.  
 
 Electrochemical Detector  
Provides sensitivity for a variety of applications needs. It is configurable with a variety of 
flow cells, variable volumes, reference electrodes, working electrodes, and working 
electrode.  
 
 Conductivity Detector  
Features a multi-electrode flow cell that offers exceptional sensitivity and stability for 
single-column or suppressor-based ion chromatography.  
                   
 ANALYTICAL METHOD VALIDATION9,10,11,12 
Validation is a basic requirement to ensure quality and reliability of the results for all 
analytical applications.  
Validation is defined as follows by different agencies:     
Method validation can be defined as per ICH, 
 “Establishing documented evidence, which provides a high degree of assurance that a 
specific activity will consistently produce a desired result or product meeting its 
predetermined specifications and quality characteristics 
European Committee (EC) 
Action of providing in accordance with the principles of good manufacturing 
practice that any procedure, process, equipment, material, activity or system actually 
14 
 
leads to the expected results. In brief validation is a key process for effective Quality 
Assurance. 
Food and Drug administration (FDA) 
Provides a high degree of assurance that specific process will consistently produce 
a product meeting its predetermined specification and quality attributes. 
World Health Organization (WHO) 
            Action of providing that any procedure, process, equipment, material, activity, or 
system actually leads to the expected results. 
SPECIFICITY/SELECTIVITY 
          The terms selectivity and specificity are often used interchangeably. According to  
ICH, the term specific generally refers to a method that produces a response for a single 
analyte only while the term selective refers to a method which provides responses for a 
number of chemical entities that may or may not be distinguished from each other. If the 
response is distinguished from all other responses, the method is said to be selective.   
LINEARITY 
             Linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional the concentration (amount) of analyte in the 
sample. A linear relationship should be evaluated across the range of the analytical 
procedure.  
RANGE 
 Range is the interval between the upper and lower concentration of the analyte in 
the sample for which it has a suitable level of precision, accuracy and linearity. 
Range is derived from linearity studies in the method validation procedure. Some 
parameters with their ranges are shown in the table below, 
15 
 
 
 
 
 
 
 
 
ACCURACY 
     Accuracy is the measure of the closeness of the experimental value is to the true value. 
Accuracy should be established across the specified range of the analytical procedure. 
A. Assay 
      1.1 Drug Substance 
Several methods of determining accuracy are available: 
a) Application of an analytical procedure to an analyte of known purity (e.g. reference 
material); 
b) Comparison of the results of the proposed analytical procedure with those of a second 
well-characterized procedure, the accuracy of which is stated and/or defined. 
c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 
 
 
Parameter Range 
Assay 
(Drug substance and finished 
product) 
Content uniformity 
Dissolution testing 
80 – 120 % 
 
70 – 130 % 
±20 % 
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 Drug Product 
Several methods for determining accuracy are available: 
a) Application of the analytical procedure to synthetic mixtures of the drug product 
components to which known quantities of the drug substance to be analysed have been 
added. 
b) In cases where it is impossible to obtain samples of all drug product components, it 
may be acceptable either to add known quantities of the analyte to the drug product or to 
compare the results obtained from a second, well characterized procedure, the accuracy 
of which is stated and/or defined. 
c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 Impurities (Quantitation) 
            Accuracy should be assessed on samples (drug substance/drug product) spiked 
with known amounts of impurities. In cases where it is impossible to obtain samples of 
certain impurities and/or degradation products 
PRECISION: 
Precision is the measure of how close the data values are to each other for a series 
of measurements under the same analytical conditions obtained from multiple sampling 
of the same homogeneous sample. Precision may be considered at three levels: 
repeatability, intermediate precision and reproducibility.  
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A. Repeatability 
 1. Injection Repeatability 
  The sensitivity or precision as measured by multiple injections of a homogeneous 
sample (prepared solution) indicates the performance of the HPLC instrument under the 
chromatographic conditions and day tested. The information is provided as part of the 
validation data and as a system suitability test. The specification, as the coefficient of 
variation in % or relative standard deviation (RSD), set here will determine the variation 
limit of the analysis. The tighter the value, the more precise or sensitive to variation one 
can expect the results. This assumes that the chromatograph does not malfunction after 
the system suitability testing has been performed. The set of four duplicate samples were 
injected sequentially. Variations in peak area and drift of retention times are noted.  
2. Analysis Repeatability 
Determination, expressed as the RSD, consists of multiple measurements of a 
sample by the same analyst under the same analytical conditions. For practical purpose, it 
is often combined with accuracy and carried out as a single study. 
 
B. Intermediate precision 
Intermediate precision was previously known as part of ruggedness. The attribute 
evaluates the reliability of the method in a different environment other than that used 
during development of the method. The objective is to ensure that the method will provide 
the same results when similar samples are analyzed once the method development phase is 
over. Depending on time and resources, the method can be tested on multiple days, 
analysts, instruments, etc. 
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C. Reproducibility 
      As defined by ICH, reproducibility expresses the precision between laboratories as 
in collaborative studies. Multiple laboratories are desirable but not always attainable 
because of the size of the firm 
 
LIMIT OF DETECTION 
  These limits are normally applied to related substances in the drug substance or 
drug product. Specifications on these limits should be provided by the regulatory 
authorities. 
A. Based on Visual Evaluation 
Visual evaluation may be used for non-instrumental methods but may also be used 
with instrumental methods. The detection limit is determined by the analysis of samples 
with known concentrations of analyte and by establishing the minimum level at which the 
analyte can be reliably detected. 
B. Based on Signal-to-Noise 
This approach can only be applied to analytical procedures which exhibit baseline 
noise. Determination of the signal-to-noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can be reliably 
detected. A signal-to-noise ratio between 3 or 2:1 is generally considered acceptable for 
estimating the detection limit. 
C. Based on the Standard Deviation of the Response and the Slope 
The detection limit (DL) may be expressed as: 
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Where, 
                 σ = the standard deviation of the response 
               S = the slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte. The estimate of s 
may be carried out in a variety of ways, for example: 
1. Based on the Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard deviation 
of these responses. 
2. Based on the Calibration Curve: 
A specific calibration curve should be studied using samples containing an analyte 
in the range of DL. The residual standard deviation of a regression line or the standard 
deviation of y-intercepts of regression lines may be used as the standard deviation. 
Recommendations: 
The detection limit and the method used for determining the detection limit should 
be presented. If DL is determined based on visual evaluation or based on signal to noise 
ratio, the presentation of the relevant chromatograms is considered acceptable for 
justification. 
In cases where an estimated value for the detection limit is obtained by calculation 
or extrapolation, this estimate may subsequently be validated by the independent analysis 
of a suitable number of samples known to be near or prepared at the detection limit. 
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LIMIT OF QUANTIFICATION 
Limit of quantification is the lowest concentration of analyte in a sample which can 
be quantitatively determined with acceptable precision and accuracy under the stated 
experimental conditions. Several approaches for determining the quantification limit are 
possible, depending on whether the procedure is a non-instrumental or instrumental. 
Approaches other than those listed below may be acceptable. 
A. Based on Visual Evaluation 
Visual evaluation may be used for non-instrumental methods but may also be used 
with instrumental methods. The quantification limit is generally determined by the 
analysis of samples with known concentrations of analyte and by establishing the 
minimum level at which the analyte can be quantified with acceptable accuracy and 
precision. 
B. Based on Signal-to-Noise Approach 
This approach can only be applied to analytical procedures that exhibit baseline noise. 
Determination of the signal-to-noise ratio is performed by comparing measured signals 
from samples with known low concentrations of analyte with those of blank samples and 
by establishing the minimum concentration at which the analyte can be reliably 
quantified. A typical signal-to-noise ratio is 10:1. 
C. Based on the Standard Deviation of the Response and the Slope 
The quantification limit (QL) may be expressed as: 
 
Where, 
             σ = the standard deviation of the response 
              S = the slope of the calibration curve 
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       The slope S may be estimated from the calibration curve of the analyte. The estimate 
of s may be carried out in a variety of ways for example: 
1. Based on Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard deviation 
of these responses. 
2. Based on the Calibration Curve 
A specific calibration curve should be studied using samples, containing an analyte in the 
range of QL. The residual standard deviation of a regression line or the standard 
deviation of y-intercepts of regression lines may be used as the standard deviation.  
 ROBUSTNESS 
     ICH defines robustness as a measure of the method's capability to remain unaffected 
by small, but deliberate variations in method parameters and provides an indication of its 
reliability during normal usage 
Examples of typical variations are: 
  Stability of analytical solutions 
  Extraction time In the case of liquid chromatography, examples of typical 
variations are 
 Influence of variations of pH in a mobile phase 
 Influence of variations in mobile phase composition 
 Different columns (different lots and/or suppliers) 
  Temperature 
  Flow rate. In the case of gas-chromatography, examples of typical variations are 
  Different columns (different lots and/or suppliers) 
  Temperature 
  Flow rate. 
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SYSTEM SUITABILITY PARAMETERS : 
System suitability tests are most often applied to analytical instrumentation. They are 
designed to evaluate the components of the analytical system in order to show that the 
performance of the system meets the standard required by the method. After the method 
has been validated an overall system suitability tests should be routinely run to determine, 
if the operating system is performing properly. 
Relative retention (selectivity):  
α = (t2-ta) / (t1-ta) 
Where, 
  α = Relative retention. 
      t1 = Retention time of the first peak measured from point of injection. 
              t2 = Retention time of the second peak measured from point of injection. 
           ta = Retention time of an inert peak not retained by the column, measured from  
point of injection. 
Theoretical plates:  
n = 16 (t / w) 2 
 Where, n = Theoretical plates.  
  t = Retention time of the component. 
               w = Width of the base of the component peak using tangent method. 
Capacity factor:  
K1 = (t2 / ta) – 1 
Where   K1 = Capacity factor. 
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Resolution:  
R = 2  ( t2 - t1 ) / ( w2 + w1 ) 
Where  R = Resolution between a peak of interest (peak 2) and the peak preceding 
it (Peak 1). 
              W2 = Width of the base of component peak 2. 
              W1 = Width of the base of component peak 1. 
Peak asymmetry:  
T = W0.05 / 2f 
Where    T = Peak asymmetry or tailing factor.  
W0.05 = Distance from the leading edge to the tailing edge of the peak, 
measured at a point 5 % of the peak height from the baseline. 
                  f = Distance from the peak maximum to the leading edge of the peak. 
Plates per meter:  
N =  n/ L 
Where   N = Plates per meter. 
         L = Column length, in meters. 
  HETP = L / n 
 
Linear fit: 
A linear calibration fit determines the best line (linear regression) for a series of 
calibration points. A minimum of two calibration points is required to determine a 
linear fit. The equation for calibrating the uncorrected amount is: 
24 
 
[Y = a X + b] 
 Where,   Y = Component area or height. 
     a = Slop of the calibration line. 
    X = Uncorrected amount. 
          b = Y- axis intercept of the calibration line.          
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2. LITERATURE REVIEW: 
 
1. HPLC and chemometric methods for the simultaneous determination of miconazole 
nitrate and nystatin. Heneedak et al., 2012. 
High-performance liquid chromatography (HPLC) and chemometric methods were 
applied to the simultaneous determination of the two nonsteroidal antifungal drugs, 
miconazole (MIC) and nystatin (NYS). The applied chemometric techniques are 
multivariate methods including classical least squares, principal component regression 
and partial least squares methods. The ultraviolet (UV) absorption spectra of the 
standard solutions of the training and validation sets in methanol are recorded in the 
range of 280-320 nm at 0.2-nm intervals. The HPLC method depends on reversed-
phase separation using a C18 column. The mobile phase consists of a mixture of 
methanol-acetonitrile-ammonium acetate buffer (pH 6; 50 mM) (60:30:10 v/v/v). The 
UV detector was set at 230 nm. The developed methods were validated and 
successfully applied to the simultaneous determination of MIC and NYS in their 
tablets. The assay results obtained using the chemometric methods were statistically 
compared to those of the HPLC method and good agreement was observed. 
2. Development and validation of a simple stability-indicating high performance 
liquid chromatographic method for the determination of miconazole nitrate in bulk 
and cream formulations María et al ., 2008. 
 
A simple and stability-indicating high performance liquid chromatographic method 
was developed and validated for the determination of miconazole nitrate in bulk and 
cream preparations. The extraction step for cream samples consisted in a warming, 
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cooling and centrifugation procedure that assures the elimination of the lipophilic 
matrix component, in order to avoid further precipitation in the chromatographic 
system. Separation was achieved on a ZORBAX Eclipse XDB – C18 
(4.6 mm × 150 mm, 5 μm particle size) column, using a mobile phase consisting of 
water, methanol and acetonitrile, in a flow and solvent gradient elution for 15 min. 
The column was maintained at 25 °C and 10 μL of solutions were injected. UV 
detection was performed at 232 nm, although employment of a diode array detector 
allowed selectivity confirmation by peak purity evaluation. The method was validated 
reaching satisfactory results for selectivity, precision and accuracy. Degradation 
products in naturally aged samples could be simultaneously evaluated, without 
interferences in the quantitative analysis. 
3.The Determination of Miconazole and its Related Production Impurities Together 
with Basic Solution Stability Studies Using a Sub 2 mm Chromatographic Column. N. 
O’Connor1 et al., 2012 
 
A selective and sensitive method for the analysis of Miconazole and its associated 
impurities is developed. The separation is carried out using a Thermo Scientific 
Hypersil Gold C18 Column (50 mm x 4.6 mm i.d., 1.9 mm particle size) with a 
mobile phase of acetonitrile–methanol–ammonium acetate (1.5 w/v) (30:32:38 v/v) 
at a flow rate of 2.5 mL/min and UV detection at 235 nm. The method is validated 
according to ICH guidelines with respect to precision, accuracy, linearity, specificity, 
robustness, and limits of detection and quantification. All parameters examined are 
found to be well within the stated guidelines. Naturally aged samples are also tested 
to determine sample stability. A profile of sample andimpurity breakdown was 
presented. The analysis time was more than halved from just under 20 min (the 
current European Pharmacopeia Method) to under 8 min (developed method) and the 
method is applicable for assay and related substance determination.. 
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4. Simultaneous determination of metronidazole and miconazole in pharmaceutical 
dosage forms by RP-HPLC. Akay et al 2002. 
A reversed-phase high performance liquid chromatography (RP-HPLC) method with 
UV detection is described for the simultaneous determination of metronidazole and 
miconazole in pharmaceutical dosage forms. Chromatography was carried out on a 
C18 reversed-phase column, using a mixture of methanol–water (40+60, v/v) as a 
mobile phase, at a flow rate of 1.0 ml min−1. Sulfamethoxazole was used as an 
internal standard and detection was performed using a diode array detector at 254 nm. 
The method produced linear responses in the concentration ranges 10–70 and 1–20 μg 
ml−1 with detection limits 0.33 and 0.27 μg ml−1 for metronidazole and micanozole, 
respectively. This procedure was found to be convenient and reproducible for analysis 
of these drugs in ovule dosage forms. 
5. Development and validation of a gradient HPLC method for the determination of 
clindamycin and related compounds in a novel tablet formulation. Daniel J. Platzer et 
al., 2006. 
A gradient reversed-phase HPLC method was developed and validated for 
potency, content uniformity, and impurity determinations for a novel tablet 
formulation containing clindamycin. The assay utilized UV detection at 214 nm and a 
Waters Xterra RP18 column (4.6 mm × 100 mm, 3.5 μm). The mobile phases were 
comprised of pH 10.5, 10 mM carbonate buffer and acetonitrile. Validation 
experiments were performed to demonstrate specificity, linearity, accuracy (i.e., 
average recovery from the formulation), precision (i.e., repeatability), limit of 
quantitation (LOQ), and robustness (i.e., sample solution stability and buffer pH 
effects on specificity). The assay was shown to be specific for clindamycin, several 
impurities, and triethyl citrate, a retained excipient that was present in the dosage 
form. The assay was proved linear (concentration versus peak area) for clindamycin 
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and several select impurities over the ranges of 70–130% and 0.1–5%, respectively. 
UV relative response factors were determined for the impurities from the linearity 
data. The accuracy of clindamycin at the targeted assay concentration was 99.2% 
(n = 3; precision = 0.12%, R.S.D.); accuracy for lincomycin, a structurally related 
impurity, was 97.4% (n = 3; precision = 3.5%, R.S.D.) at 0.1% of the targeted assay 
concentration. By demonstrating an acceptable degree of precision for lincomycin at 
this level, the LOQ was shown to be no higher than 0.1%. The chromatography was 
virtually unaffected over a mobile phase buffer pH range spanning 0.4 pH units. 
Sample solutions were stable for 72 h under ambient conditions. 
6. A New HPLC/UV method for the determination of clindamycin in dog blood 
serum.    Batzias et al ., 2004. 
A New HPLC method for the quantitative determination of clindamycin in dog blood 
serum at levels down to 80 ng/ml has been developed. Samples were deproteinised 
with acetonitrile and clindamycin was extracted with dichloromethane. 
Chromatographic analysis was carried out on a C18 reversed-phase analytical column 
in the presence of tetra-n-butylammonium hydrogen sulfate (TBA), as an ion-pairing 
agent. UV detector wavelength was set at 195 nm. The assay was validated for a 
concentration range from 80 to 6000 ng/ml serum. Good linearity was observed in the 
entire concentration range. The limit of quantification (LOQ) was 80 ng/ml and the 
limit of detection (LOD) was 60 ng/ml. Regression of accuracy data yielded an 
overall mean recovery value (±S.E.M.) of 93.98±0.42%, while precision data revealed 
coefficient of variation (CV (%)) values lower than 4.41%. The method was 
successfully applied to determine drug concentrations in serum samples from dogs 
that had been orally administered clindamycin hydrochloride. 
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7. Simple method for the assay of clindamycin in human plasma by reversed-phase 
high-performance liquid chromatography with UV detector. Cho SH et al. , 2005.  
A rapid and simple high-performance liquid chromatography (HPLC) method was 
developed and validated for the quantification of clindamycin in human plasma. After 
precipitation with 50% trichloroacetic acid (TCA) containing the internal standard, 
propranolol, the analysis of the clindamycin level in the plasma samples was carried 
out using a reverse-phase cyano (CN) column with ultraviolet detection (204 nm). 
The chromatographic separation was accomplished with an isocratic mobile phase 
consisting of acetonitrile-distilled water-7.6 mm tetramethylammonium chloride 
(TMA) (60:40:0.075, v/v/v), adjusted to pH 3.2. The proposed method was specific 
and sensitive with a lower limit of quantitation (LLOQ) of 0.2 microg/mL. This 
HPLC method was validated by examining the precision and accuracy for inter- and 
intraday analysis in the concentration range 0.2-20.0 microg/mL. The relative 
standard deviations (RSD) in the inter- and intraday validation were 6.1-14.9 and 6.0-
16.1%, respectively. In the stability test, clindamycin was found to be stable in human 
plasma during the storage and assay procedure. The present HPLC method was 
applied to the analysis of samples taken up to 12 h after a single oral administration of 
clindamycin in healthy volunteers. 
 
8.Development and validation of hplc method for simultaneous estimation of 
clindamycin phosphate, clotrimazole and tinidazole in pharmaceutical dosage form  
 Darji R B, Patel B H., 2012.  
A simple, rapid, precise, stable and accurate liquid chromatographic method 
(HPLC) was developed for the simultaneous estimation of Clindamycin phosphate 
(CLI), Clotrimazole (CLO) and Tinidazole (TIN) in pharmaceutical dosage form. A 
Kromasil C18 column (150 MM ×4.6 MM, 5 µm) in isocratic mode using ph 2.5 
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±0.01 phosphate buffer and methanol in the ratio of 40:60 as a mobile phase was 
used. The flow rate was maintained at 1 mL/min. The detection was carried out at 210 
nm. The column temperature was maintained at 40 oC. The retention time was found 
to be 2.7 min, 3.9 min and 8.5 min TIN, CLI and CLO respectively. The method was 
validated for linearity, accuracy, precision and robustness. The assay was linear over 
the range of 75-350 µg/ml. The average recovery of TIN, CLI and CLO was found to 
be 99.87±0.64 %, 100.61±1.02 % and 100.03±0.84 % respectively. The percentage 
relative standard deviation (%RSD) was found to be less than 2 % in precision study 
for each drug. The proposed method was successfully applied for the quantitative 
determination of CLI, CLO and TIN in pharmaceutical dosage form. 
9. LC Determination of Clindamycin Phosphate from Chitosan Microspheres, Muge 
et al., 2010. 
A simple, rapid and precise reverse phase LC method was adopted, modified and 
validated for the determination of clindamycin phosphate from chitosan microspheres 
prepared by spray drying method. Separation was performed using ACE5 C18 
reversed phase column (150 mm × 4.6 mm, 5 μm) with acetonitrile:phosphate buffer 
at pH 2.5 (25:75 v/v) as mobile phase. The limit of detection was 
46.43 × 10−3 μg mL−1, with UV detection at 210 nm. No interference from chitosan 
and other excipients was observed. Therefore an incorporation efficiency of 
microspheres could be determined accurately and specifically. 
 
10. Development and validation of a new HPLC analytical method for the quality 
control of   clindamycin capsules. Tamaddon et al., 2012. 
 
A simple and rapid isocratic reversed-phase high performance liquid chromatography 
(HPLC) method was developed, validated and applied for quantitation of clindamycin 
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hydrochloride in capsules. The chromatographic method employed on a Nucleodur© 
CN-RP column (250mm×4.6mm i.d., 5mm particle size) at ambient temperature. The 
mobile phases were comprised of a mixture of water and acetonitrile containing 
tetramethyl ammonium(pH 4.2) (60:40 v/v) at a flow rate of 1 ml/min. The UV 
detection was made at 204 nm. Propyl paraben was used as the internal standard. The 
average retention times for internal standard and clindamycin were 5.1 and 7.8 min 
respectively. The calibration curve was linear (r ¡Ý 0.998) over the concentration 
ranges of 2-9 µg/ml of clindamycin with detection limit of 0.3 µg/ml. Intra- and inter-
day relative standard deviations were less than 2%. No chromatographic interferences 
from the capsule excipients were found. Results showed, the reported HPLC method 
for clindamycin provides several advantages of simplicity, high specificity, accuracy 
and short run-cycle time. This proposed method was successfully used in analyzing 
the drug in dissolution media and capsule formulations. The method may be used for 
the routine quality control analysis of clindamycin pure drug and its pharmaceutical 
preparations and even under certain circumstances for the drug bio- analysis. 
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3. AIM & OBJECTIVE: 
There were no methods have been reported in the literature for the estimation of my 
method. Hence we made an attempt to develop a Assay method by HPLC for the 
estimation of Clindamycin, and Miconazole nitrate in Clindamycin 100mg and 
Miconazole nitrate 200mg Capsules (finished product) to demonstrate that the analytical 
procedure is suitable for its intended purpose.  
The report applies to analytical method validation of Clindamycin and  Miconazole 
nitrate,  in Clindamycin 100mg and Miconazole nitrate 200mg Capsules. 
 
 
4. PLAN OF WORK 
 To develop a new RP-HPLC  assay method for the estimation of clindamycin and 
miconazole nitrate in capsule dosage form. 
 And To validate the developed method. 
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5. DRUG PROFILE : 
HISTORY 
Name   : Clindamycin Phosphate 
Chemical Name:  
 
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl- L-pyrrolidinecarboxamido)-
1-thio - L- threo- a- D -galacto-octopyranoside- 2-(dihydrogen phosphate)  
 
Structure:  
 
Molecular Formula: C18H34ClN2O8PS  
 
Molecular Weight: 505.0  
 
Molecular Structure: 
   
 
CHARACTERS 
   A white or almost white powder, slightly hygroscopic, freely soluble in water, very 
slightly soluble in alcohol, practically insoluble in methylene chloride.   
 It shows polymorphism 
Action and use: 
Antibacterial.  
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Name   : Miconazole Nitrate 
 
Chemical Name:  
 
1-[(2RS)-2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole nitrate 
Structure:  
 
Molecular Formula: C18H14Cl4N2O.HNO3  
 
Molecular Weight: 479.10 
Molecular Structure: 
 
CHARACTERS: 
A white or almost white powder, very slightly soluble in water, sparingly soluble in 
methanol, slightly soluble in alcohol. 
Action and use:  Antifungal, Antifungal 
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5. MATERIALS & METHODS 
                                                                                                                          
EXPERIMENTAL DETAILS                                                                                                         
Equipment and Apparatus Used: 
 Shimadzu LC 2010 - PDA detector. 
 Chromatographic data Software: LC Solution. 
 C8 – 250 mm x 4.6 mm, 5m  
 Vacuum filter pump 
 Heating mantle 
 Ultrasonicator 
 Waterbath 
 Hot air oven 
 Single pan balance (Metler Toledo) 
 pH meter (elicos) 
 refrigerator 
 photostabilitychamber 
 high pure water-sartorius(milliq water) 
 
Reagents used: 
a. potassium dihydrogen ortho phosphate  
b. ortho phosphoric acid  
c. Acetonitrile  
d. Methanol 
e. Water (HPLC). 
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METHOD DEVELOPMENT:  
 Principle: 
Separation and quantification is based on the isocratic reverse phase chromatography 
with UV detection. 
Reagents:  
Buffer preparation: 
Weigh about 1.36 gm of potassium dihydrogen ortho phosphate into 1000ml with water 
and Adjust pH 2.5 using ortho phosphoric acid. 
Preparation of mobile Phase:  
Mixture 40 volumes of buffer, 30 Volumes Acetonitrile and 30 Volumes of Methanol 
mix well and sonicate. 
Preparation of diluent:  
Mixture 40 volumes buffer, 20 Volumes Acetonitrile and 40 Volumes of Methanol mix 
well and sonicate. 
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:   
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
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Chromatographic parameters: 
Instrument HPLC with UV/PDA detector 
Column C8 – 250 mm x 4.6 mm, 5m  
Flow rate 1.5 ml/min. 
Oven temperature 40°C±2°C 
Sample temperature Ambient 
Wavelength 210 nm 
Injection volume 20 µl 
Run time 20 minutes 
Procedure:  
Inject the Diluent, standard and sample preparations as per the following sequence. 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution 1 Analysis 
 
Record the chromatograms and measure the responses for the peak due to Clindamycin 
Phosphate and Miconazole nitrate in the standard and sample preparation. 
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Calculation: 
For Clindamycin: 
                                       TA X SWT X 10 X 100X 100 X SP X 0.812 X Avg.Fill wt. 
                               =     ----------------------------------------------------------------------- 
                                         SA X 100 X100X SWT X 10 X 100 X Label claim 
Where, 
TA        – Area of Clindamycin in sample solution. 
SWT   – Weight of Clindamycin WS taken in standard solution (mg). 
SP        - % potency of Clindamycin Phosphate WS.  
SA       – Average area of Clindamycin in standard solution. 
TWT  – Weight of medicament taken in sample solution (mg). 
Conversion Factor: Clindamycin Phosphate equivalent to Clindamycin = 0.812. 
For Miconazole: 
                                     TA X SWT X 10 X 100X 100 X SP X Avg.Fill wt. 
                               = ----------------------------------------------------------------- 
                                       SA X 100 X100X SWT X 10 X 100 X Label claim 
Where, 
TA        – Area of Miconazole in sample solution. 
SWT   – Weight of Miconazole WS taken in standard solution (mg). 
SP        - % Potency of Miconazole WS.  
SA       – Average area of Miconazole in standard solution. 
TWT  – Weight of medicament taken in sample solution (mg). 
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METHOD VALIDATION: 
VALIDATION PARAMETERS: 
THE FOLLOWING PARAMETERS SHALL BE CONSIDERED DURING 
ANALYTICAL   METHOD VALIDATION 
S.No Parameter 
1 System suitability  
2 Specificity 
3 Linearity and range 
4 Accuracy 
5 Precision 
System precision 
Intermediate precision 
6 Ruggedness 
7 Robustness 
8 Filter Validation  
9 Stability of Analytical solution ( Standard and sample 
solution) 
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 SYSTEM SUITABILITY:  
Standard solution were prepared as per test method and injected into the HPLC System. 
The system suitability parameters were evaluated for , USP Plate count, USP tailing and 
relative standard deviation for Clindamycin Phosphate and Miconazole nitrate peak area 
from the chromatograms of Six replicate injections. 
The Standard preparation, prepared by using Clindamycin Phosphate and Miconazole 
nitrate  working standard as per test method was injected six times into the HPLC 
System.  
Preparation of standard solution:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Inject the Diluent and standard solutions as per the following sequence: 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability 
Check the % RSD of areas, % RSD of RT, Theoretical plate count and tailing factor of 
Clindamycin and Miconazole peak. 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
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Theoretical plate count for Clindamycin and Miconazole peak 
from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
NMT 2.0 
 
SPECIFICITY:  
 “Specificity is the ability of the method to measure the analyte in the presence of matrix 
components. Demonstrate the specificity by identification of analytes, Blank and placebo 
interference and Peak purity of analyte.” 
Prepare the following solution for Specificity 
Bank (Diluent) 
Placebo Preparation: Weigh and transfer 1440 mg of the Placebo in to 100mL volumetric  
Flask and follow the final procedure of test preparation. 
1.0   Prepare standard as per method. 
2.0   Prepare test preparation as per method of analysis. 
Summarize the results in the table given below. 
Inject the Diluent, Placebo, Standard solution and sample solution as per the following 
sequence. 
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Solution Name No of injections Purpose 
Diluent 1 To check the interference of blank and 
placebo peaks with the main analyte. 
 
Placebo 1 
Standard solution 1 
Sample solution 1 
Acceptance Criteria: 
1) There should not be any interference by blank, Placebo peaks with the main 
analyte peak. 
2) The Purity angle index of sample peak and sample peak should not less than 0.99 
(For LC solution software). 
LINEARITY & RANGE:   
Linearity:  
                  The ability of the method to produce results is directly proportional to the 
concentration of the analyte in samples within a given range.  
 
  
Range:  
                 Is the interval between the upper and lower concentration of analyte for which i
has been demonstrated that the analytical method has a suitable level of precision, accuracy
and linearity". 
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Perform the linearity in the concentrations of 50.0%, 75.0%, 100.0%, 125.0%, and 
150.0% of working concentration of Clindamycin and Miconazole nitrate. 
Record the average area for each level and calculate slope, y- intercept & correlation 
coefficient. 
Plot the graph of respective analyte peak concentration on X- axis and area response on 
Y-axis. 
Standard Stock Solution for Linearity: 
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 30 ml of diluent, shake well to dissolve 
and make up the volume to 100ml with diluent.  
Preparation of Linearity Solutions: 
1) 50.0% solution: 
       Pipette 5ml standard stock solution to a 100.0 ml volumetric flask, make up volume 
with diluent.    
     2)   75.0% solution: 
        Pipette 7.5ml standard stock solution to a 100.0 mL volumetric flask, make up 
volume with diluent. 
 
3)  100.0% solution:  
      Pipette 10.0ml standard stock solution to a 100.0 ml volumetric flask, make up 
volume with diluent.   
 4)   125.0% solution:      
       Pipette 12.5ml standard stock solution to a 100.0 ml volumetric flask, make up 
volume with diluent. 
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 5)  150.0% solution:   
     Pipette 15.0 ml standard stock solution to a 100.0 ml volumetric flask, make up 
volume with diluent.   
Acceptance criteria:  
Correlation coeff. (r2) – Shall be NLT 0.999 
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 
To check the 
1. Correlation coeff. (r2) – 
2. y- Intercept 
 
 
50.0% solution 3 
75.0% solution: 
 
3 
100.0% solution: 
 
3 
125.0% solution: 
 
3 
150.0% solution: 
 
3 
 
Acceptance criteria:   
 
System Suitability Parameters Acceptance criteria 
Correlation coeff. r2 NLT 0.999 
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ACCURACY:  
 Accuracy is the closeness of the test results obtained by the method to the true value.  
Accuracy may often be expressed as percent recovery by the assay of known, added 
amounts of analyte. Accuracy is a measure of the exactness of analytical method. 
Accuracy shall be assessed using ‘3’ concentration (50.0%, 100.0%, and 150.0%). 
The active can be added to placebo capsules at 50.0%, 100.0%, and 150.0%   
concentration and each subsequent mixture shall be assayed.At each concentration, the 
average result shall then be expressed as a percentage of the amount added, to determine 
the recovery at each level or concentration. 
  Preparation of Standard solution: 
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Test Solution: Prepare the below test solution in triplicate 
50.0 % of test solution:                           
Weight accurately about 62mg Clindamycin Phosphate and 100mg Miconazole nitrate 
standard add about 1440mg of placebo and add 70 ml of diluent, shake well to dissolve 
and make up the volume  100ml with diluent, mix well. Filter. Pipette out 10ml solution 
to a 100.0 ml volumetric flask, make up volume with diluent.    
 
 100.0 % of test solution:                          
Weight accurately about 124mg Clindamycin Phosphate and 200mg of Miconazole 
nitrate standard add about 1440mg of placebo and add 70 ml of diluent, shake well to 
dissolve and make up the volume  100ml with diluent, mix well. Filter. Pipette out 10ml 
solution to a 100.0 ml volumetric flask, make up volume with diluent.    
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150.0 % of test solution:   
Weight accurately above 186mg Clindamycin Phosphate and 300mg Miconazole nitrate 
standard add about 1440mg of placebo and add 70 ml of diluent, shake well to dissolve 
and make up the volume 100ml with diluent, mix well. Filter. Pipette out 10ml solution to 
a 100.0 ml volumetric flask, make up volume with diluent.  
Injection sequence: 
Acceptance criteria:  
System Suitability Parameters Acceptance criteria 
Solution Name No of injections Purpose 
Diluent 1  
 
To evaluate the accuracy of method by 
recovery 
Standard solution 6 
50.0%  of test solution-1 1 
50.0%  of test solution-2 1 
50.0%  of test solution-3 1 
100.0%  of test solution-1 1 
100.0%  of test solution-2 1 
100.0%  of test solution-3 1 
150.0%  of test solution-1 1 
150.0%  of test solution-2 1 
150.0%  of test solution-3 1 
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Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
% of recovery 
 
98.0 to 102.0 
% RSD of Recovery 
 
NMT 2.0 
 
PRECISION: 
Determines closeness of agreement (expressed as Percentage Relative Standard deviation 
“% RSD”)   of the same homogenous sample under the prescribed conditions. The 
precision of the analytical method is determined by assaying 6 aliquots of homogeneous 
sample. 
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System Precision  
System precision will be tested by injecting 6 replicate injections of Clindamycin 
phosphate and Miconazole nitrate working standard solution. Calculate % RSD of six 
peak area and RT. 
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 To perform system precision 
Standard solution 6 
 
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
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The % RSD of RT for six injection of standard solution NMT 1.0 
The % RSD of Peak response for six injection of standard 
solution 
NMT 2.0 
 
Method Precision 
Method precision or reproducibility of solution will be demonstrated by analyzing the 
same Clindamycin and Miconazole nitrate Capsules batch above in 6 replicate samples. 
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:   
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence. 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
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Sample solution-1 1 To verify the precision 
Sample solution-2 1 
Sample solution-3 1 
Sample solution-4 1 
Sample solution-5 1 
Sample solution-6 1 
Acceptance Criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
% of Assay NLT 90.0 
% RSD of assay of 6 replicate sample 
 
NMT 2.0 
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Intermediate Precision:   
Intermediate precision will be demonstrated by analysing the same Clindamycin and 
Miconazole nitrate Capsules batch as above in 6 replicate samples, in the same lab but by 
a different Analyst, using a different Instrument and on a different day.  
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the precision 
Sample solution-2 1 
Sample solution-3 1 
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Sample solution-4 1 
Sample solution-5 1 
Sample solution-6 1 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
% of Assay NLT 90.0 
Confidence limits ± 5.0% 
% RSD of assay of 6 replicate samples 
 
 
NMT 2.0 
% RSD of assay of 12 replicate samples by Analyst-1 & 
Analyst-2 
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ROUGGEDNESS:  
The Ruggedness has been demonstrated by injecting six samples prepared as per the 
test preparation given the method of analysis on two different days with different 
analysts and different system (minimum two different system).Calculate the mean, 
standard deviation, relative standard deviation and confidence limits for from six test 
preparations.  
System to System variability 
The Ruggedness has been demonstrated by injecting six samples prepared as per the 
test preparation given the method of analysis on two different days with different 
analysts and different system (minimum two different system).Calculate the mean, 
standard deviation, relative standard deviation and confidence limits for assay from six 
test preparations. Summarize the results in the table given below. 
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluents 
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Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the ruggedness 
Sample solution-2 1 To verify the ruggedness 
 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
Confidence limits  
 
± 5.0% 
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% of Assay 
1. System-1 
2. System-2 
 
NLT 90.0 
 The % difference between the  Assay obtained at system-1 
and system-2 
 
NMT 2.0 
 
Column to Column variability:  
The Ruggedness has been demonstrated injecting six samples prepared as per the test 
preparation given the method of analysis on two different days with different analysts and 
different column (minimum two different columns). Calculate the mean, standard 
deviation, relative standard deviation and confidence limits for assay from six test 
preparations. Summarize the results in the table given below. 
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the ruggedness 
Sample solution-2 1 To verify the ruggedness 
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Acceptance criteria: 
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
Confidence limits  
 
± 5.0% 
% of Assay 
1. Column-1 
2. Column-2 
 
NLT 90.0 
 The % difference between the  Assay obtained at column-1 
and Column-2 
 
NMT 2.0 
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ROBUSTNESS: 
The robustness of the analytical method for assay will be demonstrated by evaluation of 
small but deliberate variations in Clindamycin and Miconazole nitrate assay method 
chromatographic parameters. The % RSD of result data will be calculated. 
The Robustness will be demonstrated for Clindamycin and Miconazole nitrate assay 
analytical method by changing chromatographic parameters. Parameters that influence 
the variations are ratio of mobile phase, flow rate, and wavelength  
Effect of variation in mobile phase composition: 
Effect of variation in Mobile phase composition (Methanol):  
To demonstrate the robustness, check the system suitability parameters by injecting 
standard preparation, by using two mobile phases, one containing 95% of the method 
organic phase composition and other containing 105% of the method organic phase 
composition. 
Preparation of mobile Phase: 100% 
Mixture 30 volumes of Acetonitrile and 30 Volumes of Methanol and 40 volume of 
buffer mix well and sonicate. 
Preparation of diluent:  
Mixture 40 volumes buffer, 20 Volumes Acetonitrile and 40 Volumes of Methanol mix 
well and sonicate. 
Preparation of mobile Phase: (95 % of methanol) 
Mixture 30 volumes of Acetonitrile and 28.5 Volumes of Methanol and 40 volume of 
buffer mix well and sonicate. 
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Preparation of mobile Phase: (105 % of methanol) 
Mixture 30 volumes of Acetonitrile and 31.5 Volumes of Methanol and 40 volume of 
buffer mix well and sonicate. 
Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the robustness 
Sample solution-2 1 To verify the robustness 
*Sequence shall be repeated with all three different mobile phase compositions. 
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Acceptance criteria:  
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin Phosphate and Miconazole 
peak from first standard injection. 
NMT 2.0 
Theoretical plate count for Clindamycin Phosphate and 
Miconazole peak from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
NMT 2.0 
% of Assay 
1. 95% methanol Mobile phase 
2. 100% methanol Mobile phase 
3.105% methanol Mobile phase 
 
NLT 90.0 
The % difference between the Assay results obtained with 
three different mobile phase composition 
 
 
NMT 2.0  
 
Effect of variation in flow rate: 
To demonstrate the robustness of test method, check the system suitability parameters 
by injecting standard preparations into the HPLC system with 1.3 ml/min, 1.5 ml/min 
and 1.7ml/min.  
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 Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the robustness 
Sample solution-2 1 To verify the robustness 
*Sequence shall be repeated with all three different flow rates 
Acceptance Criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin Phosphate and Miconazole 
peak from first standard injection. NMT 2.0 
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Theoretical plate count for Clindamycin Phosphate and 
Miconazole peak from first standard injection. 
 
NLT 2000 
 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
% of Assay 
1) 1.3 ml/minute flow rate. 
2) 1.5ml/minute flow rate. 
3) 1.7 ml/minute flow rate. 
 
NLT 90.0 
The % difference between the Assay results obtained with 
three different flow rates. 
NMT 2.0 
 
Effect of variation in Wavelength:  
To demonstrate the robustness of test method, check the system suitability parameters 
by injecting standard preparations into the HPLC system with 208nm 210nm and 
212nm Wavelength. Calculate the mean, standard deviation and relative standard 
deviation for assay from two test preparations. Summarize the results in the table given 
below. 
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Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
 Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of  diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution-1 1 To verify the robustness 
Sample solution-2 1 To verify the robustness 
 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin Phosphate and Miconazole 
peak from first standard injection. NMT 2.0 
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Theoretical plate count for Clindamycin Phosphate and 
Miconazole peak from first standard injection. 
 
NLT 2000 
The %RSD of RT for six injection of standard solution  
 
NMT 1.0 
The %RSD of Peak response for six injection of standard 
solution 
 
NMT 2.0 
% of Assay 
1) At 208 nm 
2) At 210 nm 
3) At 212 nm 
 
NLT 90.0 
The % difference between the Assay results obtained with 
three different wavelengths. 
NMT 2.0 
 
 FILTER VALIDATION: 
Filter validation of the analytical method will be demonstrated by assaying the 
homogeneous sample in duplicate (without filtration and with filtration) of the sample 
solution. The percentage RSD of the test results will be calculated. 
 
Filter validation will be demonstrated by assaying the sample with out filtration by 
centrifuging the sample solution, filtering through 0.45µm nylon filter (millex) and 
filtering the solution by Whatman filter paper no.42.    
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Standard Preparation: 
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.   
Solution Without filtration: 
Centrifuge the sample solution and inject. 
Whatman filter paper no: 42: 
Filter the sample solution with Whatman filter paper no: 42   and inject. 
0.45µm nylon filter. 
Filter the sample solution with 0.45µm nylon filter and inject 
Injection sequence 
Inject the solutions as per the following sequence: 
Solution Name No of injections Purpose 
Diluent 1 Blank 
Standard solution 6 System suitability &Quantification 
Sample solution without 
filtration(Centrifuged 
1 For filtration study 
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solution)  
2 Preparation each  
 
 
 
 
Sample solution filtered 
with Whatman filter paper 
no: 42        2 Preparation 
each 
1 
Sample solution filtered 
with 0.45µm nylon filter                 
2 Preparation each 
1 
 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak from 
first standard injection. NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak from first standard injection. 
 
NLT 2000 
The %RSD of Peak response for six injection of standard 
solution solution 
 
NMT 2.0 
% of Assay 
1.  Sample solution without filtration(Centrifuged) 
2.  Sample solution filtered with Whatman filter paper 
no: 42    
 
NLT 90.0 
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  3.Sample solution filtered with 0.45µm nylon filter   
The % difference between the Assay results obtained with 
three different filters 
NMT 2.0 
 
STABILITY OF ANALYTICAL SOLUTIONS:   
Stability of standard & sample solution will be demonstrated by injecting standard & 
sample solution with different time interval from the time of preparation. Solutions shall 
be injected once in 4 hours till the completion of 48 hours. The stability of solution shall 
be decided based on the area obtained at different time interval. This test shall be stopped 
at any time interval, if the obtained value  is not meeting the acceptance criteria. 
 Standard Preparation:  
Weigh accurately 124 mg of Clindamycin phosphate WS and 200mg of Miconazole 
nitrate WS in a 100 ml volumetric flask, add 70 ml of diluent, shake well to dissolve and 
make up the volume to 100ml with diluent. Pipette out 10ml solution to a 100.0 ml 
volumetric flask, make up volume with diluent.   
Sample Preparation:  
Collect the Medicament, take one capsule fill weight in a 100 ml volumetric flask, and 
add 30 ml of diluent, shake well to dissolve and make up the volume to 100 ml with 
diluent.  Mix well and Filter. Pipette out 10ml solution to a 100.0 ml volumetric flask, 
make up volume with diluent.  
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Injection sequence: 
Inject the solutions as per the following sequence 
Solution Name No of injections Purpose Time 
Diluent 1 Blank Sequence shall 
be started 
at Every 
4 hours 
Standard solution 1 To verify the stability 
Sample solution-1 1 
 
Acceptance criteria:   
System Suitability Parameters Acceptance criteria 
Tailing factor for Clindamycin and Miconazole peak in 
standard injection. 
NMT 2.0 
Theoretical plate count for Clindamycin and Miconazole 
peak in standard injection. 
 
NLT 2000 
For a stable solution the RSD of the peak area  
 
NMT 2.0 % 
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6.RESULTS AND DISCUSSIONS :  
 SYSTEM SUITABILITY: 
 
Injecting Clindamycin Standard and Miconazole nitrate Solution performs system 
suitability six times. The calculated Summarized results listed below 
For Clindamycin: 
 
No of Injection  
 
RT 
 
 
Response 
 
 
Tailing 
factor 
 
Theoretical 
plate 
01 2.40 174539 1.1 4248 
02 2.40 172974 1.1 4210 
03 2.40 172944 1.1 4143 
04 2.40 172789 1.1 4148 
05 2.39 173749 1.1 4295 
06 2.40 172570 1.1 4341 
Mean 2.40 173261 1.13 4231 
SD 0.00 742 0.0 79.4 
%RSD 0.17 0.4 0.7 1.9 
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For Miconazole nitrate :  
 
No of Injection  
 
RT 
 
 
Response 
 
 
Tailing 
factor 
 
Theoretical 
plate 
01 8.92 6670321 1.5 5409 
02 8.9 6655200 1.5 5389 
03 8.89 6653601 1.4 5379 
04 8.89 6647653 1.5 5451 
05 8.89 6647350 1.4 5385 
06 8.89 6642687 1.4 5465 
Mean 8.90 6652802 1.44 5413.0 
SD 0.0 9714.5 0.0 36.6 
%RSD 0.1 0.1 1.6 0.7 
 
SPECIFICITY: 
The Specificity established by injecting the following solutions    
  Blank 
  Placebo solution 
  Standard solution 
  Sample solution 
 
70 
 
The calculated Summarized results listed below. 
 RT Area Peak purity index 
Blank NA NA NA 
Placebo NA NA NA 
Working standard 
Clindamycin 
2.456 178493 0.99 
Miconazole Nitrate 9.065 6664107 0.99 
Sample 
Clindamycin 
2.413 182272 0.99 
Miconazole nitrate 8.9 6875795 0.99 
Acceptance Criteria: 
1. There should not be any interference by blank, Placebo peaks with the main 
analyte peak. 
2. The Peak purity index of standard peak in sample should not be less than 
0.9990 (For LC Solution software). 
 
LINEARITY AND RANGE: 
The linearity of the method is establishing by performing 5 test concentrations from 
50.0% to 150% of working concentrations. Assessed Linearity 50%, 75%, 100%, 125% 
and 150% each concentration 3 injection performed. The calculated Summarized results 
listed below. 
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Linearity for Clindamycin: 
Sample  Weight 
in mg 
Volum
e in 
mL 
Volume in 
mL 
Volume in 
mL 
Peak Area Conc. in  % 
Sample 
1 
124.61 100 
5mL  
100mL 
82660 
50 
Sample 
2 
7.5mL  
136013 
75 
Sample 
3 
10mL 
178432 
100 
Sample 
4 
12.5mL  
224327 
125 
Sample 
5 
15mL  
276335 
150 
 
Chart 1 – Linearity for Clindamycin:   50.0 – 150.0% w/v concentration R / peak area 
units with upper and lower 95.0% confidence limits. 
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Acceptance criteria:  
 
System Suitability Parameters Observed value Acceptance criteria 
Correlation coeff. r2 0.999  NLT 0.999 
 
Linearity for Miconazole nitrate: 
Sample  Weight 
in mg 
Volum
e in 
mL 
Volume in 
mL 
Volume in 
mL 
Peak Area Conc. in  % 
Sample 
1 
200.77 100 
5mL  
100mL 
3276552 
50 
Sample 
2 
7.5mL  
4885767 
75 
Sample 
3 
10mL 
6539879 
100 
Sample 
4 
12.5mL  
8102161 
125 
Sample 
5 
15mL  
9622955 
150 
 
Chart 1 – Linearity for Miconazole nitrate:   50.0 – 150.0% w/v Concentration R / peak 
area units with upper and lower 95.0% confidence limits. 
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Acceptance criteria:   
System Suitability Parameters Observed value Acceptance criteria 
Correlation coeff. r2 0.999 NLT 0.999 
 
 
ACCURACY: 
Accuracy is assessed using a ‘9’ determination i.e., ‘3’ concentration (50%, 100%, and 
150% each Concentration 3 determination). 
The calculated Summarized results listed below 
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FOR CLINDAMYCIN: 
Sample # 
Addition 
of Active 
to 
Excipients 
mixture 
Placebo  
Added in 
mg 
Standard 
added in 
mg 
Recovery  
in % 
Average in 
% 
RSD in 
% 
01 50.0% 1469.72 62.22 101.3 
101.1 
 
1.2 50.0% 1460.51 62.95 100.2 
50.0% 1473.13 62.7 101.9 
02 100.0% 1450.07 124.71 99.6 
99.9 
 
1.0 100.0% 1444.14 124.36 100.6 
100.0% 1446.56 124.44 99.1 
03 150.0% 1447.40 186.61 98.9 
100.0 
 
0.9 150.0% 1445.05 186.22 99.4 
150.0% 1451.8 186.79 100.7 
 Average 100.3 1.0 
Limit 98.0– 102.0 RSD 
NMT2.0 
Conclusion Complies Complies  
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FOR MICONAZOLE NITRATE: 
Sample # 
Addition 
of Active 
to 
Excipients 
mixture 
Placebo  
Added in 
mg 
Standard 
added in 
mg 
Recovery  
in % 
Average in 
% 
RSD in 
% 
01 50.0% 1469.72 100.17 101.5 
 
100.6 
 
0.2 
50.0% 1460.51 100.57 100.4 
50.0% 1473.13 100.13 100.7 
02 100.0% 1450.07 200.7 98.6 
 
101.5 
 
0.2 
100.0% 1444.14 200.07 101.6 
100.0% 1446.56 200.45 101.3 
03 150.0% 1447.40 300.13 98.6 
 
100.3 
 
0.6 
150.0% 1445.05 299.7 99.9 
150.0% 1451.8 300.46 100.7 
 Average 100.8 0.3 
Limit 98.0– 102.0 RSD 
NMT2.0 
Conclusion Complies Complies  
 
 
76 
 
Acceptance criteria: 
System Suitability Parameters Observed value 
Acceptance 
criteria 
Tailing factor for Clindamycin, 
Miconazole nitrate peak from first 
standard injection. 
1.1 
1.5 
NMT 2.0 
Theoretical plate count for Clindamycin, 
Miconazole nitrate peak from first 
standard  
injection. 
3850   
4853 
 
 
NLT 2000 
 
The %RSD of RT for six injection of 
standard solution  
1)Clindamycin 
2) Miconazole nitrate 
 
 
0.0 
0.1 
 
NMT 1.0 
The %RSD of Peak response for six 
injection of standard solution 
1)Clindamycin 
2) Miconazole nitrate 
 
 
1.3 
0.1 
 
NMT 2.0 
The Average % of recovery  
1)Clindamycin 
2) Miconazole nitrate 
 
100.3 
100.8 
98.0 to 102.0 
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The Average  % RSD of Recovery 
1)Clindamycin 
2) Miconazole nitrate 
 
1.0 
0.3 
 
NMT 2.0 
 
PRECISION: 
System Precision: 
System precision will be tested by injecting 6 replicate injections of Clindamycin, and 
Miconazole nitrate working standard solution. The calculated Summarized results listed 
below. 
For Clindamycin: 
 
No.  of Injection  
 
RT 
 
 
Response 
 
 
Tailing 
factor 
 
Theoretical 
plate 
01 2.40 174539 1.1 4248 
02 2.40 172974 1.1 4210 
03 2.40 172944 1.1 4143 
04 2.40 172789 1.1 4148 
05 2.39 173749 1.1 4295 
06 2.40 172570 1.1 4341 
Mean 2.40 173261 1.13 4231 
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SD 0.00 742 0.0 79.4 
%RSD 0.17 0.4 0.7 1.9 
 
For Miconazole nitrate 
 
No of Injection  
 
RT 
 
 
Response 
 
 
Tailing 
factor 
 
Theoretical 
plate 
01 8.92 6670321 1.5 5409 
02 8.9 6655200 1.5 5389 
03 8.89 6653601 1.4 5379 
04 8.89 6647653 1.5 5451 
05 8.89 6647350 1.4 5385 
06 8.89 6642687 1.4 5465 
Mean 8.90 6652802 1.44 5413.0 
SD 0.0 9714.5 0.0 36.6 
%RSD 0.1 0.1 1.6 0.7 
Acceptance criteria:   
System Suitability 
Parameters 
Observed value Acceptan
ce criteria Clindamycin Miconazole nitrate  
Tailing factor from first 1.1 1.5 NMT 2.0 
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standard injection. 
Theoretical plate count 
from first standard 
injection. 
 
4248 
 
5409 
 
NLT 2000 
 
The % RSD of RT for six 
injection of standard 
solution  
0.0 0.1 NMT 1.0 
The % RSD of Peak 
response for six injection of 
standard solution 
0.4 0.1 NMT 2.0 
 
Method Precision: 
Repeatability of the method performed by injecting 6 replicate injections of Clindamycin 
100mg, Miconazole nitrate 200mg capsules Sample solution. The calculated Summarized 
results listed below.  
Acceptance criteria: 
System Suitability 
Parameters 
Observed value 
Acceptance 
criteria Clindamycin 
Miconazole 
nitrate 
Tailing factor from first 
standard injection. 1.2 1.7 
NMT 2.0 
Theoretical plate count from 4371 8665 NLT 2000 
80 
 
first standard injection. 
 
The % RSD of RT for six 
injection of standard solution  0.5 0.4 
NMT 1.0 
The % RSD of Peak response 
for six injection of standard 
solution 
0.8 0.7 
NMT 2.0 
% of Assay 123.1 104.7 NLT 90.0  
% RSD of Assay of 6 replicate 
sample 
1.5 1.0 
 
NMT 2.0 
 
Intermediate Precision:   
Intermediate precision will be demonstrated by analyzing the same Clindamycin 100mg, 
Miconazole nitrate 200mg Capsules batch as above in 6 replicate samples, in the same lab 
but by a different Analyst, using a different Instrument and on a different day. 
Acceptance criteria:   
System Suitability 
Parameters 
Observed value Acceptance 
criteria Clindamycin Miconazole nitrate  
Tailing factor from 
first standard 
injection. 
1.Analyst-1 
 
 
1.1 
1.2 
 
 
1.5 
1.7 
NMT 2.0 
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2.Analyst-2 
Theoretical plate 
count from first 
standard injection. 
1.Analyst-1 
2.Analyst-2 
 
 
 
4248 
4371 
 
 
 
5409 
8665 
 
 
NLT 2000 
 
The % RSD of RT for 
six injection of 
standard solution  
1.Analyst-1 
  2.Analyst-2 
 
 
 
0.0 
0.5 
 
 
 
0.1 
0.4 
 
NMT 1.0 
The % RSD of Peak 
response for six 
injection of standard 
solution 
1.Analyst-1 
  2.Analyst-2 
 
 
 
0.4 
0.8 
 
 
 
0.1 
0.7 
NMT 2.0 
% of Assay 
1.Analyst-1 
  2.Analyst-2 
123.9 
123.1 
103.3 
104.7 
NLT 90.0  
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Confidence limits 
1.Analyst-1 
  2.Analyst-2 
1.0 
1.5 
1.1 
0.9 
±5% 
% RSD of Assay of 6 
replicate samples by  
Analyst-1  
 Analyst-2 
 
 
1.0 
1.5 
 
 
1.4 
1.0 
NMT 2.0 
% RSD of Assay of 12 
replicate samples by 
Analyst-1 & Analyst-2 
1.3 1.3 NMT 2.0 
 
RUGGEDNESS: 
The Ruggedness has been demonstrated by injecting six samples prepared as per the test 
preparation given the method of analysis on two different days with different analysts and 
different system (minimum two different system).Calculate the mean, standard deviation, 
relative standard deviation and confidence limits from six test preparations.  
System to System variability:  
The Ruggedness has been demonstrated by injecting six samples prepared as per the test 
preparation given the method of analysis on two different days with different analysts and 
different system (minimum two different system).Calculate the mean, standard deviation, 
relative standard deviation and confidence limits for Assay from six test preparations. 
Summarize the results in the table given below. 
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Acceptance criteria:  
System Suitability Parameters 
Observed value 
Acceptan
ce criteria Clindamycin 
Miconazole 
nitrate  
Tailing factor from first standard 
injection. 
1) System-1 
2) System-2 
 
 
1.1 
1.2 
 
 
1.5 
1.7 
 
NMT 2.0 
Theoretical plate count from first 
standard injection. 
1) System-1 
2) System-2 
 
 
 
4248 
4371 
 
 
 
5409 
8665 
 
 
 
NLT 2000 
 
The % RSD of RT for six injection 
of standard solution  
 1) System-1 
 2) System-2 
 
 
0.0 
0.5 
 
 
0.1 
0.4 
 
NMT 1.0 
The % RSD of Peak response for 
six injection of standard solution 
1) System-1 
 
0.4 
 
 
0.1 
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  2) System-2 0.8 0.7 NMT 2.0 
 
% of Assay 
1) System-1 
  2) System-2 
123.9 
123.1 
103.3 
104.7 
NLT 90.0 
Confidence limits 
1) System-1 
  2) System-2 
1.0 
1.5 
1.1 
0.9 
±5% 
% RSD of Assay of 6replicate 
samples by  
 1) System-1 
  2) System-2 
 
 
1.0 
1.5 
 
 
1.4 
1.0 
NMT 2.0 
% RSD of Assay of 12 replicate 
samples by System-1 & System-2 
1.3 1.3 
 
Column to Column variability: 
The Ruggedness has been demonstrated injecting six samples prepared as per the test 
preparation given the method of analysis on two different days with different analysts and 
different column (minimum two different columns). Calculate the mean, standard 
deviation, relative standard deviation and confidence limits for Assay from six test 
preparations. Summarize the results in the table given below. 
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System Suitability 
Parameters 
Observed value Acceptan
ce criteria Clindamycin Miconazole nitrate  
Tailing factor from 
first standard 
injection. 
1) Column-1 
2) Column-2 
 
 
1.1 
1.2 
 
 
1.5 
1.7 
 
NMT 2.0 
Theoretical plate 
count from first 
standard injection. 
1) Column-1 
2) Column-2 
 
 
 
4248 
4371 
 
 
 
5409 
8665 
 
 
 
NLT 2000 
 
The % RSD of RT for 
six injection of 
standard solution  
 1) Column-1 
  2) Column-2 
 
 
 
0.0 
0.5 
 
 
 
0.1 
0.4 
 
 
NMT 1.0 
The % RSD of Peak 
response for six 
injection of standard 
solution 
 
 
 
 
 
0.1 
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1) Column-1 
  2) Column-2 
0.4 
0.8 
0.7 NMT 2.0 
% of Assay 
1) Column-1 
2) Column-2 
123.9 
123.1 
103.3 
104.7 
NLT 90.0  
Confidence limits 
1) Column-1 
 2) Column-2 
1.0 
1.5 
1.1 
0.9 
±5% 
% RSD of Assay of 
6replicate samples by  
 1) Column-1 
  2) Column-2 
 
 
1.0 
1.5 
 
 
1.4 
1.0 NMT 2.0 
% RSD of Assay of 
12 replicate samples 
by Column-1 & 
Column-2 
1.3 1.3 
 
 
ROBUSTNESS: 
The Robustness will be demonstrated for Clindamycin, and Miconazole nitrate Assay 
analytical method by changing chromatographic parameters. Parameters that influence 
the variations are flow rate  and wavelengths. 
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Effect of variation in Mobile phase composition 
To demonstrate the robustness, check the system suitability parameters by injecting 
standard preparation, by using two mobile phases, one containing 95% of the method 
organic phase composition and other containing 105% of the method organic phase 
composition. 
Acceptance criteria:   
System Suitability 
Parameters 
Observed value Acceptance 
criteria Clindamycin Clindamycin 
Tailing factor for Clindamycin 
Phosphate and Miconazole peak 
from first standard injection. 
1)  95% methanol 
composition 
2) 100% methanol 
composition 
3) 105% methanol 
composition 
 
 
 
1.4 
1.2 
1.3 
 
 
 
1.5 
1.7 
1.5 
NMT 2.0 
Theoretical plate count for 
Clindamycin Phosphate and 
Miconazole peak from first 
standard injection. 
1) 95% methanol 
composition 
2) 100% methanol 
composition 
 
 
 
 
3295 
4371 
 
 
 
 
8126 
8665 
 
NLT 2000 
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   3)105% methanol 
composition 
3258 8055 
The %RSD of RT for six 
injection of standard solution 
1) 95% methanol 
composition 
2) 100% methanol 
composition 
       3)105% methanol 
composition 
 
 
0.0 
0.5 
0.3 
 
 
0.1 
0.1 
0.2 
NMT 1.0 
The %RSD of Peak response for 
six injection of standard 
solution 
1) 95% methanol 
composition 
2) 100% methanol 
composition 
        3)105% methanol 
composition 
 
 
0.4 
0.8 
0.7 
 
 
0.1 
0.1 
0.1 
NMT 2.0 
% of Assay 
1) 95% methanol 
composition 
2) 100% methanol 
composition 
3) methanol composition 
 
 
124.5 
124.4 
124.0 
 
103.7 
105.8 
104.3 
 
NLT 90.0 
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The % difference between the 
Assay results obtained with 
three different mobile phase 
composition 
 
0.2 
 
1.0 
 
NMT 2.0  
 
Effect of variation in flow rate: 
To demonstrate the robustness of test method, check the system suitability parameters by 
injecting standard preparations into the HPLC system with 1.3 ml/min, 1.5 ml/min and 1.7 
ml/min. 
System Suitability 
Parameters 
Observed value 
Acceptance 
criteria Clindamycin 
Miconazole 
nitrate  
Tailing factor from 
first standard 
injection. 
1) 1.3ml/min 
2) 1.5ml/min 
3) 1.7ml/min 
 
 
1.2 
1.1 
1.2 
 
 
1.7 
1.5 
1.7 
 
 
NMT 2.0 
Theoretical plate 
count from first 
standard injection. 
1) 1.3ml/min 
2) 1.5ml/min 
 
 
4646 
4248 
 
 
9132 
5409 
 
 
NLT 2000 
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3) 1.7ml/min 3982 8209 
The % RSD of RT for 
six injection of 
standard solution  
 1) 1.3ml/min 
2) 1.5ml/min 
  3) 1.7ml/min 
 
 
 
0.1 
0.0 
0.2 
 
 
 
0.1 
0.1 
0.1 
 
 
 
NMT 1.0 
The % RSD of Peak 
response for six 
injection of standard 
solution 
1) 1.3ml/min 
2) 1.5ml/min 
3) 1.7ml/min 
 
 
 
0.4 
0.8 
0.2 
 
 
 
0.1 
0.7 
0.1 
 
 
 
NMT 2.0 
% of Assay 
1) 1.3ml/min 
2) 1.5ml/min 
3) 1.7ml/min 
 
124.9 
123.9 
125.2 
 
104.7 
103.3 
104.4 
NLT 90.0  
The % RSD difference 
between the Assay 
results obtained with 
0.3 0.7 NMT 2.0 
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three different flow 
rates 
Effect of variation in Wavelength:  
To demonstrate the robustness of test method, check the system suitability parameters by 
injecting standard preparations into the HPLC system with 208nm 210nm and 212nm 
Wavelength. Calculate the mean, standard deviation and relative standard deviation for 
Assay from six test preparations. Summarize the results in the table given below. 
System Suitability 
Parameters 
Observed value Acceptance 
criteria Clindamycin Miconazole nitrate  
Tailing factor from first 
standard injection. 
1) 208nm 
2) 210nm 
3) 212nm 
 
 
1.1 
1.1 
1.1 
 
 
1.3 
1.5 
1.2 
 
NMT 2.0 
Theoretical plate count 
from first standard 
injection. 
1) 208nm 
2) 210nm 
3) 212nm 
 
 
 
4193 
4248 
4113 
 
 
 
5341 
5409 
5477 
 
 
 
 
NLT 2000 
 
The % RSD of RT for six 
injection of standard 
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solution  
1) 208nm 
2) 210nm 
3) 212nm 
 
 
0.0 
0.0 
0.0 
 
 
0.1 
0.1 
0.1 
 
 
NMT 1.0 
The % RSD of Peak 
response for six injection 
of standard solution 
1) 208nm 
2) 210nm 
3) 212nm 
 
 
 
0.7 
0.8 
1.8 
 
 
 
0.1 
0.7 
0.2 
 
 
 
NMT 2.0 
% of Assay 
1) 208nm 
2) 210nm 
3) 212nm 
 
123.6 
123.9 
123.4 
 
103.0 
103.3 
103.2 
NLT 90.0 
The % RSD difference 
between the Assay results 
obtained with three 
different wavelengths 
0.5 0.1 NMT 2.0 
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FILTER VALIDATIONS: 
Filter validation will be demonstrated by Assay the sample without filtration by 
centrifuging the sample solution, filtering through 0.45µm nylon filter (millex)  and 
filtering the solution by Whatman filter paper no.42.The percentage RSD of the test 
results will be calculated. 
 
System Suitability 
Parameters 
Observed value 
Acceptance 
criteria Clindamycin 
Miconazole 
nitrate  
Tailing factor from first 
standard injection. 1.1 1.5 NMT 2.0 
Theoretical plate count 
from first standard 
injection. 
4248 5409 NLT 2000 
The % RSD of RT for six 
injection of standard 
solution  
0.2 0.1 NMT 1.0 
The % RSD of Peak 
response for six injection of 
standard solution 
0.4 0.1 NMT 2.0 
 % of Assay  
1) Sample solution without 
filtration (Centrifuged) 
 2) Sample solution filtered 
 
124.5 
 
 
103.8 
 
NLT 90.0  
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with Whatman filter paper 
no: 42    
3) Sample solution filtered 
with 0.45µm nylon filter   
126.2 
 
126.2 
 
104.4 
 
104.7 
 
The % difference between 
the Assay results obtained 
with three different filters. 
0.8 0.4 
 
NMT 5.0 
 
STABILITY OF ANALYTICAL SOLUTIONS:   
The solution stability performed by injecting a homogeneous sample solution for every 
four hours interval up to 48 hours.  The % RSD of all test areas was calculated. 
 
 
Time 
Intervals 
Clindamycin Miconazole nitrate 
Standard Sample Standard Sample 
Intial 174539 219967 6670321 6887856 
4 Hour 173692 220709 6693139 6923832 
8 Hour 174461 218134 6737984 6882313 
12 Hour 173764 214756 6722905 6831903 
16 Hour 178620 219518 6769786 6829966 
20 Hour 178897 212560 6786985 6858255 
95 
 
24 Hour 173115 211639 6798956 6919299 
28 Hour 170797 213494 6847856 6959961 
32 Hour 173122 215321 6898526 7012512 
36 Hour 171526 214352 6948956 7052636 
40 Hour 168223 211256 6985265 7089653 
44 Hour 167996 207256 7078125 7195623 
48 hour 170321 209896 7025121 7187854 
Average 173006 214528 6805516 6931653 
Std dev 3342 4131 127858 121900 
RSD (%) 1.9 1.9 1.9 1.8 
 
Acceptance Criteria:   
System Suitability 
Parameters 
Observed value Acceptan
ce criteria Clindamycin Miconazole nitrate  
Tailing factor from first 
standard injection. 1.1 1.5 NMT 2.0 
Theoretical plate count 
from first standard 
injection. 
4248 5409 
 
NLT 2000 
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For a stable solution the 
RSD of the peak area not 
more than 2.0%.(Up to 48 
hour) 
1) Standard 
2) Sample 
 
 
 
1.9 
1.9 
 
 
 
1.9 
1.8 
 
 
 
NMT 2.0 
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DISCUSSION :  
 From the above data it was found that the assay value of the Clindamycin and 
miconazole nirtate  sample was found to be 102.3% and 101.3 %. And the method was 
validated , validation data as follows,  
The system suitability parameters   reveal that the values were within the specified 
limits for the proposed method. From the results shown in precision , it was found that % 
RSD is less than 2%; which indicates that the proposed method has good reproducibility.   
specificity study  reveals that the buffers  and degradation products present in the 
pharmaceutical formulations were not interfering the proposed method.  From the 
linearity Table, it was found that the drug obeys linearity with in the concentration range  
for  Clindamycin and miconazole nirtate  , From the results shown in accuracy Table , it 
was found that the percentage recovery values of pure drug were in between 99.0  to 
100.1,  indicates that the method was accurate . 
From the results shown in the ruggedness data it was observed that bench top 
stability of standard and test sample was not stable for even one day, so should use 
immediately. And the refrigerator stability of standard and test  sample was  not stable for 
even one day, so should use immediately. bench top stability of mobile phase was with in 
the limits for up to two days.from the  robustness data  we found that mobile phase 
variation (ethanol or acetonitrile) was accepted from 90-110%,  variation in the ph was 
accepted from 5.5 to 5.9, column oven temperature was between 350 to 450 , filter also 
validatd , found that there is no filter interference from the filtered and centrifuged 
samples. So filters are suitable for filtration 
          The Test procedure for Clindamycin and miconazole nirtate  capsule was validated  
and found to be linear, Specific, Precise, Accurate, Rugged and robust. 
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8. SUMMARY: 
Parameter Experiment Observation Acceptance criteria 
System 
suitability 
% RSD 
Clindamycin 
Miconazole nitrate 
 
0.4 
0.1 
The % RSD should be NMT 
2.0 
Specificity Placebo interference 
 
 
 
Placebo Interference 
and Degradation 
products  
Complies 
 
 
 
 
Complies 
The Placebo should not show 
any peak at the retention time 
of Clindamycin, Miconazole 
nitrate, peak. 
 
The Purity angle index should 
be 0.999( For LC Solution 
Software). 
Linearity and 
Range 
Coefficient of 
correlation   ( r2) 
0.999 The correlation co-efficient (r) 
should not less than 0.999. 
Accuracy  Recovery 
Clindamycin 
Miconazole nitrate 
 
100.3 and 
1.0  
100.8 and 
0.3 
 
The % Recovery should not be 
less than 98.0% and not more 
than 102.0%.The % RSD 
should not be more than 2.0. 
Precision System Precision 
Clindamycin 
Miconazole nitrate 
 
0.4 
0.1 
 
The % RSD should be NMT 
2.0 
99 
 
Method Precision 
Clindamycin 
Miconazole nitrate 
 
 
1.0 and 1.0 
1.4 and 1.1 
 
The % RSD of Assay value not 
more than 2.0.The Confidence 
limits should be ± 5.0% 
Intermediate          
Precision  
Clindamycin 
Miconazole nitrate 
 
 
1.5 and 1.5 
1.0 and 0.9 
 
The % RSD of Assay value not 
more than 2.0.The Confidence 
limits should be ± 5.0%. 
 
 
Ruggedness 
System to System  
Variability 
Clindamycin 
Miconazole nitrate 
 
 
1.3 
1.3 
 
 
The % RSD of Assay value 
2
.
0
.
Column to Column 
 Variability 
Clindamycin 
Miconazole nitrate 
 
 
1.3 
1.3 
 
 
The % RSD of Assay value  
2.0. 
100 
 
 
 
Robustness  
  
 Effect of variation in  
Mobile phase 
composition 
 Clindamycin 
Miconazole nitrate 
 
 
0.2 
1.0 
 
 
The % RSD of Assay value 
2
.
0
.
 Effect of variation in  
flow rate 
 Clindamycin 
Miconazole nitrate 
 
0.3 
0.7 
 
The % RSD of Assay value 
2
.
0
.
Effect of variation in 
wavelength 
Clindamycin 
Miconazole nitrate 
 
        0.5 
        0.1 
 
The % RSD of Assay value 
2
.
0
.
Filter validation 
Clindamycin 
Miconazole 
nitrate 
Centrifugation 
Whatman filter  
paper no:42 
0.45m nylon filter 
0.8 
0.4 
 
The  RSD of Test results NMT 
2.0.% 
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Stability of 
analytical 
solutions 
Clindamycin 
Miconazole 
nitrate 
         
 
        Standard  
Sample Solution  
 
 
1.9 and 1.9 
1.9 and 1.8 
 
The  RSD of Test results NMT 
2.0.% 
 
 
 
 
 
FIGURES : 
SYSTEM SUITABILITY:  
 
Blank: 
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Standard: 
 
Sample:  
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SPECIFICITY: 
Blank: 
 
Placebo: 
 
Standard: 
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Sample: 
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LINEARITY 
 
Linearity for 50% Solution: 
 
 
Linearity for 75% Solution:  
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Linearity for 100% Solution: 
 
Linearity for 125% Solution:  
 
 
 
 
 
 
 
 
107 
 
Linearity for 150% Solution: 
 
 
 
 
LINEARITY CURVE FOR CLINDAMYCIN 
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LINEARITY CURVE FOR MICONAZOLE NITRATE: 
 
ACCURACY 
Accuracy for 50% Solution: 
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] 
 
Accuracy 100% Solution: 
 
 
Accuracy 150% Solution: 
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9. CONCLUSION : 
 
The proposed analytical method is simple, economical, rapid, reproducible and accurate 
for the estimation of Clindamycin and Miconazole nitrate Capsules. A newer RP-HPLC 
method was developed for formulations. The proposed method gives reliable assay 
results with short analysis time using mobile phase of sodium acetate tri hydrate ,  
acetonitrile  &ethanol.. 
            The above method does not suffer from any interference due to common 
excipients or degradation products. Thus it was show that proposed methods could be 
successfully applied to estimate commercial pharmaceutical products containing 
Clindamycin and Miconazole nitrate. Thus the above studies and findings will enable the 
quantification of the drug for future investigation in the field of analytical chemistry. 
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